Hormonal Contraceptive Use and the Prevalence of Endometriotic Lesions at Different Regions within the Peritoneal Cavity
Table 2
Hormonal contraceptives and the presence of endometriotic lesions in defined regions.
Single region, (%)
Multiple region, (%)
OR (95% CI)
value
Single versus multiple regions
All
81
80
No hormone
41 (50.6)
47 (58.8)
HC
40 (49.4)
33 (41.3)
0.72 (0.39–1.34)
0.3435
Absence, (%)
Presence, (%)
OR (95% CI)
value
Ovarian
All
72
89
No hormone
32 (44.4)
57 (64.0)
HC
40 (55.6)
32 (36.0)
0.45 (0.24–0.88)
0.0167
Peritoneal
All
51
110
No hormone
28 (54.9)
61 (55.4)
HC
23 (45.1)
49 (44.5)
0.98 (0.50–1.91)
1.000
RVS
All
101
58
No hormone
57 (56.4)
30 (51.7)
HC
44 (43.6)
28 (48.3)
1.21 (0.63–2.31)
0.6210
A Fisher’s exact test was used to determine if the incidence of endometriotic lesions in particular locations was significantly different under HC use.
